The Use of Reduction of Splenomegaly as a Parameter for Therapeutic Response in Hepatic Schistosomiasis

  • Mohamed Aly El-Dydamouny Department of Community and Preventive Medicine Faculty of Medicine El-Minya University El-Minya Egypt
Keywords: Schistosomiasis, splenomegaly, praziquante/

Abstract

DOI: http://dx.doi.org/10.5915/23-2-15068

The effectiveness of praziquantel in the treatment of hepatic schistosomiasis was studied in 30 patients with bilharzial splenomegaly. Reduction in splenomegaly was used as a parameter of therapeutic success. Twenty one out of 30 patients improved when treated by repeated doses of praziquantel. The number of administered doses necessary to achieve clinical improvement was directly related to the pretreatment size of the spleen. The patients were divided into three groups according to the size of the spleen; up to 5 cm below the costal margin in the mid-clavicular line (Group 1), between 5-10 cm in Group 2, and more than 10 cm in Group 3. The rate of improvement was 100% in Group I, 75% in Group 2, and 25% in Group 3.

Author Biography

Mohamed Aly El-Dydamouny, Department of Community and Preventive Medicine Faculty of Medicine El-Minya University El-Minya Egypt
M.D.
Department of Community and Preventive Medicine
Faculty of Medicine
El-Minya University
El-Minya
Egypt
Published
1991-04-01
Section
Original Articles